Delta and Omicron-adapted Sputnik V vaccine announced

23 August 2022

The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund have announced the development of the Sputnik V vaccine specifically adapted against Delta and Omicron variants of coronavirus.

The news comes just days after Moderna and BioNTech/Pfizer announced their own bivalent Omicron vaccines.

Over the course of the pandemic the Gamaleya Center has studied the new and emerging variants of SARS-CoV-2 and adapting the Sputnik V vaccine to them. The newest version of the vaccine, Sputnik V, has been Delta and Omicron-adapted. This version of the vaccine is the most promising specifically adapted to new variants as compared to those tailored against the combination of the original strain and Omicron variant.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK